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Aberrant NMDA receptor (NMDAR) activity contributes to several neurological disorders, but direct 40 
antagonism is poorly tolerated therapeutically. The GluN2B cytoplasmic C-terminal domain (CTD) 41 
represents an alternative therapeutic target since it potentiates excitotoxic signaling. The key 42 
GluN2B CTD-centred event in excitotoxicity is proposed to involve its phosphorylation at Ser-1303 43 
by Dapk1, that is blocked by a neuroprotective cell-permeable peptide mimetic of the region. 44 
Contrary to this model, we find that excitotoxicity can proceed without increased Ser-1303 45 
phosphorylation, and is unaffected by Dapk1 deficiency in vitro or following ischemia in vivo. 46 
Pharmacological analysis of the aforementioned neuroprotective peptide revealed that it acts in a 47 
sequence-independent manner as an open-channel NMDAR antagonist at or near the Mg2+ site, 48 
due to its high net positive charge. Thus, GluN2B-driven excitotoxic signaling can proceed 49 
independently of Dapk1 or altered Ser-1303 phosphorylation. 50 




NMDA receptor (NMDAR) -mediated excitotoxicity plays a key role in acute neurological disorders 54 
such as stroke and traumatic brain injury, neuronal loss in Huntington's disease, and is also 55 
implicated in synapto-toxicity in Alzheimer's disease 1-7. Most NMDARs are comprised of two 56 
obligate GluN1 subunits and two GluN2 subunits 8, with GluN2A and GluN2B predominant in the 57 
forebrain 9-13. GluN2 subunits have long, evolutionarily divergent cytoplasmic C-terminal domains 58 
(CTDs) which we have shown can differentially associate with signalling molecules 14-17 and 59 
differentially signal to cell death: the CTD of GluN2B (CTD2B) potentiates excitotoxicity more 60 
strongly than that of GluN2A 14. 61 
 While multiple pathways contribute to excitotoxicity 18, the mechanism by which CTD2B is 62 
thought to potentiate excitotoxicity is upstream of all of them 6,19,20. The mechanism is centred on 63 
Ser-1303 of CTD2B, within a region of the CTD unique to GluN2B, and with which CaMKIIα is known 64 
to interact and phosphorylate 21,22. It was reported that in response to ischemia or excitotoxic insults, 65 
a different kinase, Dapk1, causes Ser-1303 phosphorylation which increases NMDAR-dependent 66 
ionic flux 19. Consistent with this, Dapk1-/- neurons were reported to be resistant to excitotoxicity, and 67 
a cell-permeable peptide mimetic of the CTD2B region around Ser-1303 disrupted Ser-1303 68 
phosphorylation and was neuroprotective 19. 69 
 Given that the GluN2B-Dapk1 pathway is prominent in contemporary models of excitotoxicity 70 
6,20 we sought to investigate this pathway further. Dapk1 has not hitherto emerged from proteomic 71 
post-synaptic density screens 23-30, and we failed to detect it in a recent proteomic analysis of native 72 
NMDAR supercomplexes 17. Moreover, the use of cell-permeable peptides to draw wide-ranging 73 
mechanistic conclusions can be problematic without extensive controls. We investigated whether 74 
Dapk1-mediated Ser-1303 phosphorylation indeed represents the major reason why CTD2B 75 
promotes excitotoxicity signaling better than CTD2A, using approaches that include analysis of a 76 
new Dapk1 knockout mouse and the generation of a knock-in mouse with a targeted phospho-77 
mimetic mutation of the CAMKIIα/putative Dapk1 interaction site. 78 
 79 
Results  80 
Excitotoxic insults do not induce GluN2B Ser-1303 phosphorylation 81 
We first examined the influence of excitotoxic conditions on GluN2B Ser-1303 phosphorylation in 82 
cortical neurons using a phospho-(Ser-1303)-specific antibody (Millipore 07-398), previously used 83 
and validated by several groups 31-33.  84 
We confirmed that the antibody is capable of detecting changes in Ser-1303 phosphorylation 85 
in neurons: phospho-GluN2B(Ser-1303) levels in cortical neurons, as assayed by western blot using 86 
this antibody, are lowered after incubation of cortical neurons with the general kinase inhibitor 87 
staurosporine, and increased modestly by a cocktail of phosphatase inhibitors okadaic acid and FK-88 
506 (Figure 1–figure supplement 1a,b, Figure 1–source data 4). As further evidence of specificity, 89 
we found that the antibody completely failed to react with GluN2B in which we had engineered 90 
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mutations (L1298A/R1300N/S1303D) into the site for a separate study (Figure 1–figure supplement 91 
1c,d).  92 
 We found that bath application of NMDA at excitotoxic concentrations failed to induce 93 
significant Ser-1303 phosphorylation (Figure 1a,1b, Figure 1–source data 1). At the late timepoint 94 
(60 min, 50 µM NMDA) we observed a decline in Ser-1303 phosphorylation (Figure 1a,b, Figure 1–95 
figure supplement 1e,f, Figure 1–source data 5) as well as a decline in total levels of GluN2B, 96 
consistent with observations of others who have reported partial calpain-mediated cleavage and 97 
degradation of the NMDAR CTD 34,35. These observations in DIV10 cortical neurons were also 98 
repeated at DIV16 (Figure 1–figure supplement 1g,h, Figure 1–source data 6). We also saw no 99 
increase in Ser-1303 phosphorylation in response to oxygen-glucose deprivation (OGD) (Figure 100 
1c,d, Figure 1–source data 2), contrary to previous reports 19. 101 
 To determine whether Dapk1 plays any role in the GluN2B Ser-1303 phosphorylation status, 102 
we obtained a Dapk1-/- mouse line, created by the International Mouse Phenotyping Consortium by 103 
targeted deletion of exon 4 on a C57Bl/6 background (the same strain as the Dapk1-/- mouse 104 
generated by Tu et al (2010)). The mice had normal fertility, viability and body weight 105 
(http://www.mousephenotype.org, MGI:1916885). We confirmed that Dapk1-/- neurons expressed no 106 
Dapk1 (Figure 1e). We compared GluN2B phospho-Ser-1303 levels in cortical neurons obtained 107 
from Dapk1-/- and Dapk1+/+ littermates and found no difference in basal levels, nor any difference in 108 
the lowered level that we observe at longer periods of NMDA exposure (Figure 1e,f, Figure 1–109 
source data 3). Thus in our hands, Dapk1 does not influence GluN2B Ser-1303 phosphorylation 110 
status under basal or excitotoxic conditions. 111 
 112 
Excitotoxic and ischemic neuronal death can proceed independently of Dapk1 113 
We next addressed the more general point of the role of Dapk1 in excitotoxic neuronal death. 114 
Compared to cortical neurons cultured from their wild-type littermates, we observed no difference in 115 
NMDAR-dependent excitotoxic neuronal death in Dapk1-/- neurons at either DIV10 or DIV16 (Figure 116 
2a, Figure 2–source data 1; Figure 2b, Figure 2–source data 2) and no difference in OGD-induced 117 
neuronal death (Figure 2c, Figure 2–source data 3), contrary to previous reports. NMDAR currents 118 
were also no different in Dapk1-/- vs. Dapk1+/+ neurons (Figure 2d, Figure 2–source data 4). 119 
 We then studied the influence of Dapk1 deficiency on ischemic neuronal death in vivo. We 120 
employed a model of transient global ischemia model (bilateral common carotid artery occlusion) 121 
used previously to show a protective effect of Dapk1 deficiency 19. Adult mice exposed to a transient 122 
(20 min) period of global ischemia showed characteristic selective neuronal death within the 123 
hippocampus, particularly the CA1 and CA2 regions. However, Dapk1-/- and Dapk1+/+ mice exhibited 124 
similar levels of infarction (Figure 2e-h, Figure 2–source data 5), contrary to previous reports 19. 125 
These observations collectively indicate that excitotoxic and ischemic neuronal death in vitro and in 126 





TAT-NR2BCT is a direct NMDAR antagonist 131 
In support of the Dapk1 hypothesis for CTD2B-derived excitotoxicity, a cell-permeable (TAT-fused) 132 
peptide mimetic of the GluN2B amino acids 1292-1304 (TAT-KKNRNKLRRQHSY: TAT-NR2BCT) 133 
was reported to prevent NMDAR-dependent GluN2B Ser-1303 phosphorylation, and excitotoxicity 134 
19. We observed that 50 µM TAT-NR2BCT, the concentration used previously 
19, was toxic to 135 
neurons (Figure 3–figure supplement 1a, Figure 3–source data 4), so we used a concentration 10 136 
times lower (5 µM). We found that 5 µM TAT-NR2BCT completely prevents NMDA-induced 137 
excitotoxicity (Figure 3–figure supplement 1b, Figure 3–source data 5). This was surprising, given 138 
that we did not see a role for Dapk1 in excitotoxicity (Figure 2). However, further analysis revealed 139 
the explanation: at 5 µM, TAT-NR2BCT potently inhibited NMDAR currents, acting immediately and 140 
without any need for a preincubation period (Figure 3a-d, Figure 3–source data 1), and in a manner 141 
that was not readily washed out upon removal of peptide (data not shown). TAT-NR2BCT was 142 
custom synthesized for our studies by Genscript, and we found that NR2BCT(1292-1304)-TAT, a 143 
pre-made peptide sold by Merck Millipore was a similarly potent NMDAR antagonist (n=8, Figure 3–144 
figure supplement 1c). A scrambled version of TAT-NR2BCT (TAT-sNR2BCT) was similarly 145 
neuroprotective and similarly antagonistic at the NMDAR (Figure S3b, Figure 3a-d). One potential 146 
explanation for the NMDAR antagonistic properties of TAT-NR2BCT is the high positive charge of the 147 
peptide (+15 at neutral pH). To investigate this, we designed an arginine-rich peptide of high net 148 
positive charge (+15-same as TAT-NR2BCT)of sequence: RRR TQN RRN RRT SRQ NRR RSR 149 
RRR) which strongly antagonized NMDAR currents, and another peptide of net neutral charge (NIN 150 
IHD VKV LPG GMI KSN DGP PIL), which had a much weaker effect (Figure 3a, Figure 3–source 151 
data 1). Taken together these data suggest that the net positive charge of TAT-NR2BCT is primarily 152 
responsible for its NMDAR-antagonistic properties. We hypothesized that TAT-NR2BCT may be an 153 
open channel blocker drawn partly into the pore by its high net positive charge and bind near the 154 
internal Mg2+ binding site. Consistent with this, the presence of Mg2+ (a pore blocker) reduced the 155 
effectiveness of TAT-NR2BCT's antagonism (Figure 3e, Figure 3–source data 2). Another prediction 156 
of this hypothesis is that TAT-NR2BCT would be more effective at antagonising NMDARs under 157 
open-channel conditions. To test this, NMDAR currents were measured, after which neurons were 158 
incubated in TAT-NR2BCT (5 µM) for 60 s in the presence of zero glycine+100 µM AP5 ("block (1)") 159 
to ensure minimal channel opening (closed channel conditions). 60 s was chosen because under 160 
conditions of NMDAR agonism this is sufficient time to achieve maximal blockade. After 60 s, both 161 
TAT-NR2BCT and AP5 were removed from the bathing medium and NMDAR currents were 162 
subsequently re-measured (150 µM NMDA + 100 µM glycine, zero Mg2+). The very slow off-rate of 163 
the TAT-NR2BCT enabled the peptide's effects on currents to be measured in the absence of the 164 
peptide in the medium. TAT-NR2BCT was then applied for a second 60 s ("block (2)") either under 165 
the same "closed channel conditions" or under "open channel conditions" (100 µM glycine, 150 µM 166 
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NMDA). After 60 s TAT-NR2BCT was removed from the bathing medium and NMDAR currents 167 
measured for a 3rd time. The NMDAR current remaining at the 2nd and 3rd measurements was 168 
calculated as a fraction of the initial current. We found that the 2nd peptide incubation (block (2)) 169 
significantly increased the proportion of NMDAR inhibition when it occurred under open-channel 170 
conditions, but not under closed channel conditions (Figure 3f, Figure 3–source data 3, further 171 
evidence in favour of a pore-centred binding site for TAT-NR2BCT. Thus, the unintended NMDAR 172 
antagonistic properties TAT-NR2BCT explain its anti-excitotoxic effects. 173 
 174 
Discussion 175 
Dapk1-mediated GluN2B Ser-1303 phosphorylation, and consequent enhancement of toxic Ca2+ 176 
influx through extrasynaptic NMDARs lies at the heart of current models of excitotoxicity and of the 177 
central role of the GluN2B CTD in this process 6,20, but our study suggests that this needs to be re-178 
appraised. Our observations regarding the (lack of) impact of Dapk1 gene deletion on neuronal 179 
vulnerability to excitotoxic and ischemic conditions is at odds with previous reports 19. The Dapk1-/- 180 
mouse that we used was generated independently of the one generated by Tu et al., although there 181 
is no a priori reason why the two lines should behave differently at this fundamental level, 182 
particularly given the very similar genetic background (C57BL/6).  183 
 The potent inhibition of NMDAR currents by TAT-NR2BCT at a concentration up to 100 times 184 
lower than that used previously 19 suggests a simple explanation for its neuroprotective effects 185 
independent of Dapk1. We are unable to explain why we observed similar effects of TAT-NR2BCT 186 
and its scrambled version, while a selective effect of TAT-NR2BCT was previously reported 
19. Both 187 
scrambled versions employed had identical sequences, and the potent NMDAR antagonistic 188 
properties of our scrambled peptide are consistent with its neuroprotective properties. 189 
 One outstanding question is the basis for the modestly reduced excitotoxicity in young 190 
neurons when NMDARs lack the GluN2B CaMKII site. We know that NMDAR currents are 191 
unaffected, as is the proportion of NMDARs at synaptic vs. extrasynaptic sites, an important factor 192 
in excitotoxicity 36, are unaltered. This is consistent with other studies which have concluded that 193 
mutation of this site does not affect NMDAR biophysical properties 37,38. More generally, the basis 194 
for CTD2B-mediated excitotoxicity 14 remains incompletely understood. Exchanging the CTD of 195 
GluN2B with that of GluN2A by targeted exon exchange reduces vulnerability to excitotoxicity 14, 196 
and performing the reciprocal swap increases vulnerability (SM and GEH, unpublished 197 
observations), strongly supportive of a key role for CTD2B. An ongoing avenue of investigation is 198 
focussed on understanding the extent to which the composition of the native NMDAR signaling 199 
complex is altered by manipulating the endogenous GluN2 CTDs in our panel of knock-in mice. We 200 
hypothesize that alterations to the complex may disturb signaling to pro-death events such as NO 201 
production, NADPH oxidase activation, oxidative stress, calpain activation and mitochondrial Ca2+ 202 
overload 6,20,36,39-43. Of note, we recently showed that the CTD of GluN2B (as opposed to that of 203 
GluN2A) is critically required for formation of 1.5 MDa NMDAR supercomplexes 17. Thus, regions 204 
 7 
unique to GluN2B (of which the CaMKII site is one) play a role in higher order signal complex 205 
assembly and this may underlie the key role of CTD2B in downstream excitotoxicity 14. 206 
 207 
Materials and Methods 208 
 209 
Neuronal culture, Dapk-/- mice, induction of excitotoxicity and oxygen-glucose deprivation 210 
Cortical mouse neurons were cultured as described 44 at a density of between 9-13 x 104 neurons 211 
per cm2 from E17.5 mice with Neurobasal growth medium supplemented with B27 (Invitrogen, 212 
Paisley, UK). Stimulations of cultured neurons were done in most cases after a culturing period of 9-213 
11 days during which neurons develop a network of processes, express functional NMDA-type and 214 
AMPA/kainate-type glutamate receptors, and form synaptic contacts. Other experiments were 215 
performed at DIV 16. Dapk-/- mice (colony name: H-Dapk1-B11-TM1B, MGI Allele Name: 216 
Dapk1tm1b(EUCOMM)Hmgu, RID:MGI:5756958) were generated by MRC Harwell from targeted 217 
ES cells made by The European Conditional Mouse Mutagenesis Program, as part of the 218 
International Mouse Phenotyping Program. Dapk-/- genotyping reactions were performed using the 219 
following primers: A = 5-AGAGAAACTGAGGCACCTGG -3’, B =, 5’-220 
CATCCAAAGTCCACAGCCAC-3’, C=5’-CCAGTTGGTCTGGTGTCA-3’ Primer pair A-B recognised 221 
the wild-type allele and amplified a product of 322 bp. Primer pair B-C recognised the mutant allele 222 
corresponding to a product of 468 bp. PCR reactions were performed using the following cycling 223 
conditions: 15 min at 95°C; 36 cycles of 45 s at 94°C, 45 s at 60°C and 1 min at 72°C; and 10 min at 224 
72°C.  225 
 To apply an excitotoxic insult, neurons were first placed overnight into a minimal defined 226 
medium 45 containing 10% MEM (Invitrogen), 90% Salt-Glucose-Glycine (SGG) medium (46; SGG: 227 
114 mM NaCl, 0.219 % NaHCO3, 5.292 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM 228 
Glycine, 30 mM Glucose, 0.5 mM sodium pyruvate, 0.1 % Phenol Red; osmolarity 325 mosm/l,47). 229 
Where used, TAT-NR2BCT or TAT-sNR2BCT (5 µM) was incubated for 1h prior to the excitotoxic 230 
insult. Neurons were then treated with NMDA (Tocris Bioscience, Bristol, UK) at the indicated 231 
concentrations for 1 h, after which medium was changed to NMDA-free. After a further 23 h, 232 
neurons were fixed and subjected to DAPI staining and cell death quantified by counting (blind) the 233 
number of shrunken, pyknotic nuclei as a percentage of the total. To induce oxygen-glucose 234 
deprivation, a previously described approach was used 48,49. Briefly, cells were washed and 235 
incubated in glucose-free SGG (see formulation above, but with glucose replaced by mannitol) that 236 
had been previously degassed with 95% N2-5% C02. The cells were then placed in an anoxic 237 
modular incubator chamber for 120 min (as compared to cells washed and incubated in normoxic 238 
glucose-containing SGG). For analysis of excitotoxicity, approximately 800-1000 cells were 239 
analysed per condition, per replicate (repeated across several replicates), the observer blind to 240 
genotype and experimental condition.  241 
 242 
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Electrophysiological recording and analysis 243 
Coverslips containing cortical neurons were transferred to a recording chamber perfused (at a flow 244 
rate of 3-5 ml/min) with an external recording solution composed of (in mM): 150 NaCl, 2.8 KCl, 10 245 
HEPES, 2 CaCl2, 1 MgCl2, 10 glucose and 0.1 glycine, pH 7.3 (320-330 mOsm). Patch-pipettes 246 
were made from thick-walled borosilicate glass (Harvard Apparatus, Kent, UK) and filled with a K-247 
gluconate-based internal solution containing (in mM): potassium gluconate 141, NaCl 2.5, HEPES 248 
10, EGTA 11; pH 7.3 with KOH). Electrode tips were fire-polished for a final resistance ranging 249 
between 4-8 MΩ. Currents were recorded at room temperature (21 ± 2°C) using an Axopatch 200B 250 
amplifier (Molecular Devices, Union City, CA). Neurons were voltage-clamped at –60 mV or +40 mV 251 
as indicated, and recordings were rejected if the holding current was greater than –100 pA (–60 mV 252 
only) or if the series resistance drifted by more than 20% of its initial value (<25 MΩ). All NMDA 253 
currents were evoked by 150 µM NMDA + 100 µM glycine except figure 2D where 50µM NMDA + 254 
100 µM glycine was used. Whole-cell currents were analyzed using WinEDR v3.2 software (John 255 
Dempster, University of Strathclyde, UK). The approximate number of cells to be recorded was 256 
estimated in order to detect a 25% difference in the parameter under study, powered at 80%, based 257 
on the standard deviation of data previously published by the laboratory 14,50,51. 258 
 To determine the ifenprodil-sensitivity of neurons, whole cell NMDA currents were recorded 259 
(as described above) followed by the inclusion of 3 µM ifenprodil in the recording solution for a 260 
blocking period of 90 seconds. The whole cell NMDA current was the re-assessed, with 3 µM 261 
ifenprodil included, and the percentage block calculated. A similar protocol was used to determine 262 
the competing effect of Mg2+ and TAT-NR2BCT except a blocking period of 60 seconds was used 263 
and TAT-NR2BCT was not included when NMDA currents were re-assessed; this may have led to a 264 
small washout but we deemed this as negligible due to the slow-off rate of NR2BCT. The 265 
membrane potential-dependency of TAT-NR2BCT-induced NMDAR antagonism was determined by 266 
applying the peptide for 50-60 seconds after initial steady state at both - 60mV or + 40 mV. 267 
To investigate the use dependency of TAT-NR2BCT, we minimized the possibility of the 268 
NMDAR channel opening by spontaneous release of glutamate by removing glycine from the ACSF 269 
and co-applying 100 µM AP5. Glycine was added back to the ACSF to measure NMDA currents 270 
and to facilitate the block of TAT-NR2BCT in the open channel configuration. 271 
 272 
Western blotting 273 
Western blotting was performed as described 52. In order to minimize the chance of post-274 
translational modifications during the harvesting process, neurons were lysed immediately after 275 
stimulation in 1.5x LDS sample buffer (NuPage, Life Technologies) and boiled at 100°C for 10 min. 276 
Approximately 10 µg of protein was loaded onto a precast gradient gel (4-16%) and subjected to 277 
electrophoresis. Western blotting onto a PVDF membrane was then performed using the Xcell 278 
Surelock system (Invitrogen) according to the manufacturer's instructions. Following the protein 279 
transfer, the PVDF membranes were blocked for 1 h at room temperature with 5% (w/v) non-fat 280 
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dried milk in TBS with 0.1% Tween 20. The sample size was calculated based on previous 281 
experimental observations of reporting the effect and standard deviation of NMDA-induced Ser-282 
1303 phosphorylation 19. The membranes were incubated at 4°C overnight with the primary 283 
antibodies diluted in blocking solution: Anti phospho-(Ser-1303) GluN2B (1: 2000, Millipore), anti-284 
Dapk1 (1:8000, Sigma), anti-GluN2B (C-terminus, 1:8000, BD Transduction Laboratories), anti-beta 285 
actin (1:200000, Abcam). For visualisation of Western blots, HRP-based secondary antibodies were 286 
used followed by chemiluminescent detection on Kodak X-Omat film. Western blots were digitally 287 
scanned and densitometric analysis was performed using Image J. All analysis of GluN2B 288 
phosphorylation was normalized to total GluN2B. 289 
 290 
Bilateral common carotid artery occlusion 291 
Mice were housed in individually-ventilated cages (in groups of up to five mice) under specific 292 
pathogen-free conditions and standard 12 h light/dark cycle with unrestricted access to food and 293 
water. All experiments using live animals were conducted under the authority of UK Home Office 294 
project and personal licences and adhered to regulations specified in the Animals (Scientific 295 
Procedures) Act (1986) and Directive 2010/63/EU and were approved by both The Roslin Institute’s 296 
and the University of Edinburgh’s Animal Welfare and Ethics Committees. Experimental design, 297 
analysis and reporting followed the ARRIVE guidelines (https://www.nc3rs.org.uk/arrive-guidelines) 298 
where possible. The sample size was calculated based on the experimental observations of 299 
reporting the effect and standard deviation of BCCAO-induced neuronal loss in both wild-type and 300 
Dapk1–/– 19, whose experimental observations using n=7 per genotype we retrospectively calculated 301 
were powered at >99%. 302 
 Transient bilateral common carotid artery occlusion (BCCAO) was performed in Dapk1–/– 303 
and wild-type male control mice under isoflurane anaesthesia (with O2 and N2O). The operator was 304 
unaware of genotype. Core body temperature was maintained at 37 ± 0.5ºC throughout the 305 
procedure with a feedback controlled heating blanket (Harvard Apparatus, UK). Both common 306 
carotid arteries were exposed and dissected from surrounding tissues and occluded by application 307 
of an aneurysm clip for 20 min. Clips were removed, the neck wound sutured and topical local 308 
anaesthetic (lidocaine/prilocaine) was applied. Mice were recovered on a heated blanket for 4-6h 309 
and then returned to normal housing. After a 3 day recovery, mice were anaesthetised and perfused 310 
transcardially with saline followed by 4% paraformaldehyde. Brains were removed and rostral and 311 
caudal blocks prepared using a brain matrix (Harvard Apparatus). Blocks were post-fixed in 4% 312 
paraformaldehyde for 24 h and processed to paraffin blocks. Sections (6m) were cut on a 313 
microtome (Leica) and stained with haematoxylin and eosin. Ischaemic neuronal death was 314 
quantified in the CA1 and CA2 regions of the hippocampus which are the most sensitive regions in 315 
this model. Ischaemic (dead) neurons were identified morphologically in two regions of interest 316 
(ROIs) in CA1 and the entire CA2 bilaterally. Data are expressed as the number of dead neurons as 317 
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a % of total neurons in the ROI and show the mean of both hemispheres for each region. All 318 
processing and analysis was performed with the operator blind to genotype. 319 
 320 
Statistical analysis, equipment and settings. 321 
Statistical testing involved a 2-tailed paired Student's t-test, or a one- or two-way ANOVA followed 322 
by an appropriate post-hoc test, as indicated in the legends. Cell death analyses for both in vitro 323 
and in vivo experiments were performed blind to the genotype/experimental condition. For all cell 324 
death, western blot analyses and in vitro and in vivo cell death experiments, the value of 'N' was 325 
taken as the number of independent biological replicates, defined as independently performed 326 
experiments on material derived from different animals. For western blots, we used 327 
chemiluminescent detection on Kodak X-Omat film, and linear adjustment of brightness/contrast 328 
applied (Photoshop) equally across the image, maintaining some background intensity. In any 329 
cases where lanes from non-adjacent lanes are spliced together,lanes are always from the same 330 
blot, processed in the same way, and the splicing point is clearly marked. Pictures of cells were 331 
taken on a Leica AF6000 LX imaging system, with a DFC350 FX digital camera.  332 
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Figure Legends 502 
 503 
Figure 1. Neither Dapk1 nor excitotoxic insults increase GluN2B phosphorylation on Ser-504 
1303. A,B) Strong excitotoxic insults induce GluN2B Ser-1303 dephosphorylation at later 505 
timepoints. Western analysis of extracts from cortical neurons treated as indicated with NMDA or 506 
bicuculline (50 µM) plus 4-amino pyridine (250 µM). (F(2,24)=3.904, P=0.034 (Two-way ANOVA). 507 
*P= 0.0053 (Sidak's post-hoc test; 95% CI of diff: 0.1777 to 1.139, comparison to control without 508 
NMDA treatment, N=3). C,D) Mimicking ischemic conditions triggers dephosphorylation of GluN2B 509 
Ser-1303 in an NMDAR-dependent manner. Oxygen-glucose deprivation (OGD) applied for 120 min 510 
± MK-801 (10 µM). F(1,12)=6.69, P=0.024 (Two-way ANOVA). *P= 0.0003 (Sidak's post-hoc test, 511 
95% CI of diff: 0.3289 to 0.9172, N=4). E,F) Dapk1 deficiency does not influence basal or NMDA-512 
induced GluN2B Ser-1303 phosphorylation status. Neurons were treated ± 50 µM NMDA for 60 min. 513 
F(1,10)=345.1, P<0.0001 (Two-way ANOVA, Con vs. NM). *P<0.0001 (both, compared to Con of 514 
that genotype, 95% CI of diff: 0.6384 to 0.9342, and 0.6411 to 0.9826 (reading left to right), N=4 515 
WT, N=3 KO; with "N" defined as a distinct culture from a distinct animal). ns: F(1,10)=0.5418, 516 
P=0.4786. 517 
 518 
Figure 2. Excitotoxic and ischemic insults are not ameliorated by Dapk1 deficiency. A, B) 519 
NMDA-induced neuronal death is independent of Dapk1. Cortical neurons at DIV10 (A) or DIV16 (B) 520 
were treated as indicated for 1 h, with neuronal death assessed at 24 h. The p values relate to a 521 
two-way ANOVA test of differences between WT and Dapk–/– neurons (F(1,10) = 0.2676, n=6 WT, 6 522 
KO (DIV10); F(1,7)=0.8871, 2-way ANOVA, n=4 WT, 5 KO (DIV16)). For each condition/genotype 523 
combination, 800-1000 cells were analysed per biological replicate. C) OGD-induced neuronal 524 
death is independent of Dapk1. Cortical neurons at DIV10 were subjected to OGD for 120 min, 525 
before being returned to control medium. Neuronal death was assessed at 24 h. No genotype-526 
dependent difference was observed (F (1,12)=0.5062, P=0.490, but a strong influence of OGD was 527 
observed: F (1,12) = 63.54, P<0.0001, two-way ANOVA. #P=0.0002, 0.0002 (reading left to right); 528 
Sidak's post-hoc test comparing control to OGD condition (n=4 WT, n=4 KO). D) Dapk1 deficiency 529 
does not influence NMDAR currents. NMDAR currents were measured in n=16 WT cells (from 4 530 
separate cultures) and n=25 KO cells (from 6 separate cultures). Currents were normalized to the 531 
mean current recorded from WT cells recorded on that precise day. P=0.411 (t=0.831, df=39), 532 
unpaired t-test. E-G) Dapk1 deficiency does not influence vulnerability to ischemia in vivo. Adult 533 
age-matched mice (n=14 WT; n=16 KO) were subjected to 20 min bilateral common carotid artery 534 
occlusion, sacrificed at 3 d, and pathology analysed. CA1/2 (E): P=0.555 (t=0.598, df=28); CA1 535 
(F):P=0.572 (t=0.572, df=28), CA2 P=0.592(G, t=0.543, df=28). Scale bar = 50 µm. 536 
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 537 
Figure 3. Both TAT-NR2BCT and TAT-sNR2BsCT are direct NMDAR antagonists. A-D) Both 538 
TAT-NR2BCT and TAT-sNR2BCT (scrambled version of TAT-NR2BCT) immediately antagonize 539 
NMDAR currents upon extracellular exposure. NMDA-induced currents were recorded under whole-540 
cell voltage clamp, with the indicated peptides (at 5 µM) applied approximately 5 s after NMDA (to 541 
allow NMDAR currents to reach steady state). Arg-rich refers to the arginine-rich positively charged 542 
peptide; Neutral refers to the neutral peptide-see main text for sequences of these as well as TAT-543 
NR2BCT and TAT-sNR2BCT. NMDA-induced NMDAR currents were monitored for a further 45 s and 544 
the percentage drop in currents calculated, compared to no peptide at all (Con) which represents a 545 
measure of natural desensitization over this period. P<0.0001 (one-way ANOVA). *P<0.0001, 546 
Sidak's post-hoc test (n=8 of all conditions). Example traces shown in (B) (C) and (D). Scale bar: 15 547 
s, 500 pA. E) NMDAR antagonism by TAT-NR2BCT is inhibited by Mg
2+ blockade. NMDAR currents 548 
were measured, after which neurons were incubated in TAT-NR2BCT (5 or 0.5 µM) for 60 s in the 549 
presence or absence of 1 mM Mg2+, after which NMDAR currents were measured again (in zero 550 
Mg2+, no peptide). P<0.0001 (one-way ANOVA, F(1,22)=47.16 (effect of [Mg2+])). *P<0.0001, 551 
P=0.0007, Sidak's post-hoc test (zero Mg2+: n=6 (0.5 µM), n=7 (5 µM); 1 mM Mg2+: n=6 (0.5 µM), 552 
n=7 (5 µM)). F-H) NMDAR antagonism by TAT-NR2BCT is more effective on open channels. See 553 
main text for experimental details. P<0.0001 (two-way ANOVA, comparing initial current with 554 
subsequent measurements: F (2, 45) = 25.22. P<0.0001 (two-way ANOVA, comparing 'closed-then-555 
closed' protocol (grey bars, n=8) with 'closed-then-open' protocol (black bars, n=9): F (1, 45) = 556 
18.26. #P=0.003, 0.0009 (Sidak's post-hoc test), comparing to initial currents. *P<0.0001 (Sidak's 557 
post-hoc tests), comparisons indicated. (G) shows example recordings taken during the consecutive 558 
"closed" then "closed" channel protocol. (H) shows example recordings taken during the 559 




Figure Supplement Legends 564 
 565 
Figure 1–figure supplement 1. A,B) Neurons were treated with staurosporine (STS, 1 µM) or FK-566 
506 (FK, 5 µM) + okadaic acid (OA, 10 µM) for one hour, after which protein was harvested and 567 
western analysis for Phospho- (GluN2B Ser-1303) levels performed. P=0.0023 (1-way ANOVA). 568 
Individual P-values left-to-right: 0.026, 0.047 (n=8 (FK+OA); n=4 (STS). C) Schematic depicting the 569 
amino-acid changes resulting from mutations of the Grin2b gene in the GluN2B∆CaMKII allele. D) 570 
Example Phospho- (GluN2B Ser-1303) western blot illustrating the lack of immunoreactivity of the 571 
mutated domain in extracts from GluN2B∆CaMKII/∆CaMKII neurons. E,F) timecourse of GluN2B Ser-1303 572 
phosphorylation status in response to NMDA treatment (50 µM). F(5,10)=4.019, P=0.023 (one-way 573 
ANOVA). *P=0.041 (Sidak's post-hoc test (n=3), 95% CI of diff 0.01897 to 1.024). G,H) Experiment 574 
 16 
performed as per Figure 1a except neurons were at DIV16 rather than DIV10. F (2, 24) = 5.324, 575 
P=0.0122 (two-way ANOVA). *P=0.0022 (Sidak's post-hoc test (N=3)). 576 
 577 
 578 
Figure 3–figure supplement 1. A) Neurons were treated where indicated with 50 µM TAT-NR2BCT 579 
for 1 h, with death assessed after 24 h. B) Neurons were pre-treated where indicated with TAT-580 
NR2BCT or TAT-sNR2BCT for 1 h, prior to 1h NMDA treatment at the indicated concentrations, in the 581 
continued presence of the peptides where used. Subsequently, both NMDA and peptide were 582 
removed from the medium and death assessed after a further 23 h. P<0.0001 (effect of peptide: 583 
two-way ANOVA, F(2,40)=76.13, n=3-4). *P= 0.0027, 0.0039 (20 µM), <0.0001, <0.0001 (30 µM), 584 
<0.0001, <0.0001 (50 µM), <0.0001, <0.0001 (100 µM), Sidak's post-hoc test. C) Example trace 585 
from an experiment where NMDA-induced currents were recorded under whole-cell voltage clamp, 586 
with NR2BCT(1292-1304)-TAT (5 µM, Merck Millipore) applied approximately 5 s after NMDA (to 587 
allow NMDAR currents to reach steady state). NMDA-induced NMDAR currents were monitored to 588 
determine the degree of blockade. The trace is representative of 8 cells recorded this way, with the 589 
peptide blocking by 63 ± 3 %. Scale bar = 5 s, 500 pA.  590 
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Figure 1–source data 1. Data relating to Figure 1b 593 
Figure 1–source data 2. Data relating to Figure 1d 594 
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Figure 2–source data 1. Data relating to Figure 2a 599 
Figure 2–source data 2. Data relating to Figure 2b 600 
Figure 2–source data 3. Data relating to Figure 2c 601 
Figure 2–source data 4. Data relating to Figure 2d 602 
Figure 2–source data 5. Data relating to Figure 2e-g 603 
Figure 3–source data 1. Data relating to Figure 3a 604 
Figure 3–source data 2. Data relating to Figure 3e 605 
Figure 3–source data 3. Data relating to Figure 3f 606 
Figure 3–source data 4. Data relating to Figure 3–figure supplement 1a 607 
Figure 3–source data 5. Data relating to Figure 3–figure supplement 1b 608 
 609 
 610 
 611 
 612 
 613 
 17 
 614 





